Skip to main content
. Author manuscript; available in PMC: 2021 Jun 15.
Published in final edited form as: Oncogene. 2020 Dec 15;40(5):997–1011. doi: 10.1038/s41388-020-01563-x

Fig. 5.

Fig. 5.

AR agonist treatment blocked Y537S mutant metastasis. A. Immunoblot analysis of MCF-7 parental (n=4) and YS1 (n=5) primary /metastatic pairs grown with E2 withdrawal. B. Western blot analysis of MCF-7 parental, YS1, DG, and YS30 clones cultured in 5% CSS media for 4 days GAPDH was used as loading control. C. Mice with WHIM20 PDX tumors were supplemented with E2, and randomized to –E2, -E2+DHT or –E2+Enz for total of 4 months. Time to tumor doubling was calculated using Kaplan-Meier method. Data were analyzed using Log-rank (Mantel-Cox) Test. P= 0.10 for DHT vs vehicle control and P= 0.07 for MDV vs vehicle control. D. Macrometastasis frequency was calculated and displayed chi-square and fisher exact analyses, * P =0.002. E and F. ER and PR total score IHC staining two-sided Student’s t-test was performed to test significance. *P <0.05, **P <0.01,* P <0.001, NS=Not significant. G. Western blot analyses of WHIM20 primary tumors; GAPDH was used as a loading control. H. Western blot analyses of MCF-7 YS1 cells; performed using in vitro cell line protein lysis and GAPDH was used as a loading control. Cells were starved for 48 hours in 5% CSS, and then treated with hormones for 24 hours.